Efficacy and safety of Iranian made Deferasirox (Osveral®)in Iranian major thalassemic patients with transfusional iron overload: A one year prospective multicentric open-label non-comparative study

DARU, Journal of Pharmaceutical Sciences

Volumn 19, Issue 3, 2011, Pages 240-248

  Eshghi, P ^a   Farahmandinia, Z ^b   Molavi, M ^c   Naderi, M ^d   Jafroodi, M ^e   Hoorfar, H ^f   Davari, K ^g   Azarkeivan, A ^h   Keikhaie, B ⁱ   Ansari, S ^j   Arasteh, M ^k  

^a SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b KERMAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c HORMOZGAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d ZAHEDAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^e GUILAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^f ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^g ZANJAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^h IRANIAN BLOOD TRANSFUSION ORGANIZATION   (Iran)

ⁱ AHVAZ JUNDISHAPUR UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^j TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^k Samen ol Hojaj center for special disease   (Iran)

more..

Author keywords

Deferasirox; Efficacy; Iron chelation; Osveral ; Safety; Thalassemia

Indexed keywords

DEFERASIROX; FERRITIN; OSVERAL; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CHILD; CREATININE BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; ERYTHROCYTE TRANSFUSION; ETHNIC GROUP; FEMALE; FERRITIN BLOOD LEVEL; HUMAN; IRANIAN; IRON CHELATION; IRON OVERLOAD; LIVER DYSFUNCTION; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PATIENT COMPLIANCE; PATIENT MONITORING; PRESCHOOL CHILD; PROSPECTIVE STUDY; RECOMMENDED DRUG DOSE; SCHOOL CHILD; SEX RATIO; SIDE EFFECT; THALASSEMIA MAJOR;

EID: 80053455572     PISSN: 15608115     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Britton RS, Leicester KL, Bacon BR. Iron toxicity and chelation therapy. Int J Hematol. 2002;76: 219-228
2. Wood JC, Tyszka JM, Carson S, Nelson MD, Coates TD. Myocardial iron loading in transfusion-dependent thalassemia and sickle cell disease. Blood. 2004;103:1934-1936
3. Brittenham GM, Griffth PM, Nienhuis AW, McLaren CE, Young NS, Tucker EE, Allen CJ, Farrell DE, Harris JW. Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major. N Engl J Med. 1994;331: 567-573.
4. Gabutti V, Piga A. Results of long-term iron-chelating therapy. Acta Haematol. 1996;95:26-36.
5. Cunningham MJ, Acklin EA, Neufeld EJ, Cohen R. Complications of beta-thalassemia major in North America Blood. 2004; 104:34-9.
6. Arboretti R, Tognoni G, Alberti D. Pharmacosurveillance and quality of care of thalassaemic patients. Eur J Clin Pharmacol. 2001;56:915-922.
7. Piga A, Caglioti C, Fogliacco E, Tricta F. Comparative effects of deferiprone and deferoxamine on survival and cardiac disease in patients with thalassemia major: a retrospective analysis. Haematologica. 2003;88:489-496.
8. Anderson LJ, Wonke B, Prescott E, Holden S, Walker JM, Pennell D. Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in beta-thalassemia. Lancet. 2002; 360: 516-520.
9. Pennell DJ, Berdoukas V, Karagiorga M, Ladis V, Piga A, Aessopos A, Gotsis ED, Tanner MA, Smith GC, Westwood MA, Wonke B, Galanello R. Randomized controlled trial of deferiprone or deferoxamine in betathalassemia major patients with asymptomatic myocardial siderosis. Blood. 2006;107:3738-3744.
10. Cohen AR, Galanello R, Piga A, Dipalma A, Vullo C, Tricta F. Safety profle of the oral iron chelator deferiprone: a multicenter study. Br. J Haematol. 2000;108:305-312.
11. P Eshghi Complications of Combined Treatment with Deferiprone and Desferrioxamine in Thalassemic Patients. IJMS. 2007;32:40-44
12. http://clinicaltrials.gov/ct2/results?term=deferasirox/ accessed on 6/17/2011
13. http://www.exjade.com/index.jsp?lightbox=global-hcp/ accessed on 6/17/2011
14. Cappellini MD, Cohen A, Piga A, Bejaoui M, Perrotta S, Agaoglu L, Aydinok Y, Kattamis A, Kilinc Y, Porter J, Capra M, Galanello R, Fattoum S, Drelichman G, Magnano C, Verissimo M, Athanassiou-Metaxa M, Giardina P, Kourakli-Symeonidis A, Janka-Schaub G, Coates T, Vermylen C, Olivieri N, Thuret I, Opitz H, Ressayre-Djaffer C, Marks P, Alberti D.A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with b-thalassemia. Blood.2006; 107: 3455-3462
15. Taher A, El-Beshlawy A, Elalfy MS, Al Zir K, Daar S, Habr D, Kriemler-Krahn U, Hmissi A, Al Jefri A. Efficacy and safety of deferasirox, an oral iron chelator, in heavily iron-overloaded patients with beta-thalassaemia: the ESCALATOR study. Eur J Haematol. 2009;82:458-65
16. Cappellini MD, Porter J, El-Beshlawy A, Li CK, Seymour JF, Elalfy M, Gattermann N, Giraudier S, Lee JW, Chan LL, Lin KH, Rose C, Taher A, Thein SL, Viprakasit V, Habr D, Domokos G, Roubert B, Kattamis A; EPIC Study Investigators.Tailoring iron chelation by iron intake and serum ferritin: the prospective EPIC study of deferasirox in 1744 patients with transfusion-dependent anemias. Haematologica. 2010;95: 557-566
17. http://www.osvahpharma.com/index.php?module=cdk&func=loadmodule&system=cdk&sismodule=user/content_view.php&sisOp=view&id=6&ctp_id=18&cnt_id=806www.fdo.ir/Drug/Fa/Downloads/ ShowSection.aspx?fd=11 accessed on 6/17/2011
18. http://fdo.behdasht.gov.ir/ accessed on 6/17/2011
19. www.accessdata.fda.gov/drugsatfda_docs/label/2008/021882s004lbl.pdf/ accessed on 6/17/2011
20. Yavarian M, Karimi M, Bakker E, Harteveld CL, Giordano PC. Response to hydroxyurea treatment in Iranian transfusion-dependent beta-thalassemia patients. Haematologica. 2004;89:1172-1178
21. http://www.fda.gov/Drugs/ResourcesForYou/Consumers/QuestionsAnswers/ucm100100.htm/ accessed on 6/17/2011
22. Porter J, Galanello R, Saglio G, Neufeld EJ, Vichinsky E, Cappellini MD, Olivieri N, Piga A, Cunningham MJ, Soulières D, Gattermann N, Tchernia G, Maertens J, Giardina P, Kwiatkowski J, Quarta G, Jeng M, Forni GL, Stadler M, Cario H, Debusscher L, Della Porta M, Cazzola M, Greenberg P, Alimena G, Rabault B, Gathmann I, Ford JM, Alberti D, Rose C. Relative response of patients with myelodysplastic syndromes and other transfusion-dependent anaemias to deferasirox (ICL670): a 1-yr prospective study. European Journal of Haematology. 2008; 80:168-176.
23. Cappellini M-D, Cohen A, Eleftheriou A, Piga A, Porter J, Taher A. Guidelines for the Clinical Management of Thalassaemia 2nd Edition Revised. Thalassaemia International Federation publication. Nicosia,Team up Creation Ltd. 2008;35-40
24. Taher A, Cappellini MD, Vichinsky E, Galanello R, Piga A, Lawniczek T, Clark J, Habr D, Porter JB. Efficacy and safety of deferasirox doses of >30 mg/kg per d in patients with transfusion-dependent anaemia and iron overload. British Journal of Haematology, 2009; 147: 752-759
25. ®) during a Median of 2.7 Years of Treatment in Heavily Iron-Overloaded Patients with β-Thalassemia Blood (ASH Annual Meeting Abstracts), Nov 2008; 112: 5409.
26. ®) with up to 4.5 Years of Treatment in Patients with Thalassemia Major: A Pooled Analysis Blood (ASH Annual Meeting Abstracts), Nov 2008; 112: 5411.
27. ®) in Pediatric Patients with β-Thalassemia: Update of 4.7-Year Efficacy and Safety from Extension Studies Blood (ASH Annual Meeting Abstracts), Nov 2008; 112: 3883.
28. ®) in a large Group of Regularly Transfused Patients with β-Thalassemia Major Blood (ASH Annual Meeting Abstracts), Nov 2008; 112: 3878
29. www.accessdata.fda.gov/drugsatfda_docs/label/2009/021882s006lbl.pdf/ accessed on 6/17/2011
30. http://www.exjade.com/exjade-safety/long-term-safety-profle.jsp?lightbox=global-hcp/ accessed on 6/17/2011